Biotinoyl Tripeptide-1

Identity and Structure

Biotinoyl tripeptide-1 is a cosmetic peptide formed by conjugating biotin (vitamin B7) to the tripeptide Gly-His-Lys — the same GHK core found in GHK-Cu and palmitoyl tripeptide-1. The biotin group is linked via an amide bond to the N-terminal glycine, substituting for the palmitoyl tail of Pal-GHK and the copper ion of GHK-Cu. It is the hair-follicle-directed member of the GHK family.

The molecule was introduced commercially by Sederma (Croda) as the peptide component of Procapil, a branded scalp-care complex that combines biotinoyl tripeptide-1 with apigenin (a citrus-derived flavonoid) and oleanolic acid (extracted from olive leaves). Procapil became a common ingredient in hair-loss serums and scalp tonics from the late 2000s onward, marketed toward early androgenetic alopecia and diffuse thinning rather than established baldness.

Intended Mechanism

The conceptual basis of biotinoyl tripeptide-1 is hair-follicle anchoring — the integrity of the attachment between the hair shaft and the surrounding dermal sheath. Weakened anchoring is one proposed driver of shedding and of the shortened anagen phase characteristic of pattern hair loss. The GHK fragment is hypothesized to stimulate dermal papilla cells and to support extracellular-matrix components (laminins, collagen IV) that reinforce the dermal-epidermal junction around the follicle. The biotin conjugation is marketed as aiding follicular delivery of the peptide, though mechanistic data on whether biotin meaningfully enhances cutaneous uptake of a small peptide remains limited.

Within the Procapil complex, biotinoyl tripeptide-1 is positioned against the downstream effects of dihydrotestosterone (DHT) — the androgen most implicated in androgenetic alopecia — not by blocking 5-alpha-reductase (finasteride's mechanism) or the androgen receptor, but by supporting the structural integrity and metabolic state of the follicle under chronic DHT pressure. Apigenin and oleanolic acid contribute vasodilatory and 5-alpha-reductase-modulating activity to the combination.

Clinical Evidence

Peer-reviewed human data on biotinoyl tripeptide-1 as an isolated ingredient is thin. Manufacturer-sponsored studies on the broader Procapil complex have reported reductions in shedding and modest increases in hair density over 3–4 months of daily topical use, with typical effect sizes in the low single digits of percentage-point change in density — a meaningfully smaller magnitude than the clinical response to topical minoxidil or oral finasteride. Independent replication is limited, and the few comparator trials that have included Procapil alongside established agents have placed it meaningfully behind those agents on objective endpoints.

The honest summary: biotinoyl tripeptide-1 and the Procapil complex sit in the category of adjunctive hair-care ingredients. There is a plausible mechanistic story and a modest clinical signal. There is not adequate evidence to treat it as a substitute for minoxidil, finasteride, dutasteride, or procedural interventions in people with clinically meaningful androgenetic alopecia.

Formulation and Application

Biotinoyl tripeptide-1 is typically used at low parts-per-million active-peptide levels in leave-on scalp serums, lotions, and specialized shampoos. Evening application is standard — partly for extended contact time without interference from styling products, and partly because follicular mitotic activity peaks during sleep. The ingredient is usually formulated alongside its Procapil partners, though standalone scalp serums exist. Compatibility with common actives (niacinamide, panthenol, caffeine, adenosine) is good; as with most peptides, strongly acidic vehicles and oxidizing co-actives should be avoided.

Safety and Regulatory Status

Biotinoyl tripeptide-1 is a cosmetic ingredient with no drug approval anywhere in the world. Its real-world safety profile across more than a decade of retail exposure is uneventful — scalp irritation is rare and typically attributable to other components of finished products (e.g., alcohol carriers, fragrance). It is not systemically absorbed at meaningful levels, is not on any anti-doping list, and requires no prescription.

Bottom Line

Biotinoyl tripeptide-1 is best understood as a supporting ingredient in the scalp-care category — reasonable to add alongside evidence-based therapies, not a substitute for them. Consumers with active androgenetic alopecia are better served by starting with minoxidil and, where appropriate, a 5-alpha-reductase inhibitor under medical supervision, and treating biotinoyl tripeptide-1 as a complementary maintenance ingredient rather than a primary intervention.